Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axcella Health Inc. - Common Stock (NQ:AXLA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axcella Health Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-... 
Via Benzinga
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
From Axcella Therapeutics
Via Business Wire
Axcella Kickstarts Long COVID Phase 2 Clinical Trial
Axcella Therapeutics Inc (NASDAQ: AXLA) has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long... 
Via Benzinga
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
From Axcella Therapeutics
Via Business Wire
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
From Axcella Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) ... 
Via Benzinga
Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021
From Axcella Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Axcella To Test NASH Candidate In Long COVID Patients
Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
From Axcella Therapeutics
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the... 
Via Benzinga
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
From Axcella Therapeutics
Via Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Axcella Announces Upcoming Investor Conference Presentation
From Axcella
Via Business Wire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation
Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella (NASDAQ: AXLA) uses endogenous metabolic modulators (EMMs) to treat complex diseases, including liver... 
Via Benzinga
Axcella Health Inc. (NASDAQ: AXLA) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
Via Investor Brand Network
Topics Derivatives
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Piper Sandler boosted the price target for Adobe Inc. (NASDAQ: ADBE) from $600 to $670. Adobe shares fell 3.5% to $623.50 in pre-market trading. Keybanc reduced the price target... 
Via Benzinga
Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials
Image Provided By Pixabay The American Journal of Gastroenterology recently published findings from a clinical study of AXA1125, a groundbreaking potential treatment for... 
Via Benzinga
Axcella Announces Upcoming Investor Conference Presentation
From Axcella
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers INmune Bio (NASDAQ:INMB) shares ... 
Via Benzinga
Breakthrough Multi-Targeted Drug Candidates Puts Axcella at Forefront of Liver Disease Treatment Market
Image Provided By Unsplash Liver diseases like cirrhosis and nonalcoholic steatohepatitis (NASH) are deadly and afflict millions of Americans with debilitating mental and physical... 
Via Benzinga
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
From Axcella
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.